News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Stentys Concludes Clinical Trial Ahead of Plan


2/2/2012 7:19:38 AM

PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing™ Stent to treat Acute Myocardial Infarction (AMI), announced today that the “APPOSITION III” clinical study successfully enrolled 1,000 patients suffering from a severe heart attack and that the final results of the examination 30 days after treatment will be presented during the upcoming EuroPCR international cardiology congress.

Read at BioSpace.com


comments powered by Disqus
Stentys
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES